Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus

Am J Cardiol. 2005 Jun 1;95(11):1386-8. doi: 10.1016/j.amjcard.2005.01.092.

Abstract

The effect of ramipril (an angiotensin [AT]-converting enzyme inhibitor), telmisartan (an AT-II type 1 receptor blocker), or their combination on inflammation and lipid peroxidation was assessed in 37 patients with type 2 diabetes who were free of coronary artery disease. All regimens were associated with a significant reduction of C-reactive protein and oxidized low-density lipoprotein cholesterol serum levels (p <0.001). These results further enlighten the mechanisms underlying the cardiovascular beneficial effect of renin-AT system inhibition.

Publication types

  • Comparative Study

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Benzimidazoles / therapeutic use*
  • Benzoates / therapeutic use*
  • C-Reactive Protein / analysis*
  • Cholesterol, LDL / blood*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Oxidation-Reduction
  • Ramipril / therapeutic use*
  • Telmisartan

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzimidazoles
  • Benzoates
  • Cholesterol, LDL
  • C-Reactive Protein
  • Ramipril
  • Telmisartan